Limit of detection in different matrices of 19 commercially available rapid antigen tests for the detection of SARS-CoV-2
Abstract In the context of the coronavirus disease 2019 (COVID-19) pandemic there has been an increase of the use of antigen-detection rapid diagnostic tests (Ag-RDT). The performance of Ag-RDT vary greatly between manufacturers and evaluating their analytical limit of detection (LOD) has become hig...
Guardado en:
| Autores principales: | , , , , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Nature Portfolio
2021
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/ce468b9e5ac9426487c5b215c756ebef |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:ce468b9e5ac9426487c5b215c756ebef |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:ce468b9e5ac9426487c5b215c756ebef2021-12-02T17:25:43ZLimit of detection in different matrices of 19 commercially available rapid antigen tests for the detection of SARS-CoV-210.1038/s41598-021-97489-92045-2322https://doaj.org/article/ce468b9e5ac9426487c5b215c756ebef2021-09-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-97489-9https://doaj.org/toc/2045-2322Abstract In the context of the coronavirus disease 2019 (COVID-19) pandemic there has been an increase of the use of antigen-detection rapid diagnostic tests (Ag-RDT). The performance of Ag-RDT vary greatly between manufacturers and evaluating their analytical limit of detection (LOD) has become high priority. Here we describe a manufacturer-independent evaluation of the LOD of 19 marketed Ag-RDT using live SARS-CoV-2 spiked in different matrices: direct culture supernatant, a dry swab, and a swab in Amies. Additionally, the LOD using dry swab was investigated after 7 days’ storage at − 80 °C of the SARS-CoV-2 serial dilutions. An LOD of ≈ 5.0 × 102 pfu/ml (1.0 × 106 genome copies/ml) in culture media is defined as acceptable by the World Health Organization. Fourteen of 19 Ag-RDTs (ActiveXpress, Espline, Excalibur, Innova, Joysbio, Mologic, NowCheck, Orient, PanBio, RespiStrip, Roche, Standard-F, Standard-Q and Sure-Status) exceeded this performance criteria using direct culture supernatant applied to the Ag-RDT. Six Ag-RDT were not compatible with Amies media and a decreased sensitivity of 2 to 20-fold was observed for eleven tests on the stored dilutions at − 80 °C for 7 days. Here, we provide analytical sensitivity data to guide appropriate test and sample type selection for use and for future Ag-RDT evaluations.Ana I. Cubas-AtienzarKonstantina KontogianniThomas EdwardsDominic WoodingKate BuistCaitlin R. ThompsonChristopher T. WilliamsEdward I. PattersonGrant L. HughesLisa BaldwinCamille EscadafalJilian A. SacksEmily R. AdamsNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-8 (2021) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Medicine R Science Q |
| spellingShingle |
Medicine R Science Q Ana I. Cubas-Atienzar Konstantina Kontogianni Thomas Edwards Dominic Wooding Kate Buist Caitlin R. Thompson Christopher T. Williams Edward I. Patterson Grant L. Hughes Lisa Baldwin Camille Escadafal Jilian A. Sacks Emily R. Adams Limit of detection in different matrices of 19 commercially available rapid antigen tests for the detection of SARS-CoV-2 |
| description |
Abstract In the context of the coronavirus disease 2019 (COVID-19) pandemic there has been an increase of the use of antigen-detection rapid diagnostic tests (Ag-RDT). The performance of Ag-RDT vary greatly between manufacturers and evaluating their analytical limit of detection (LOD) has become high priority. Here we describe a manufacturer-independent evaluation of the LOD of 19 marketed Ag-RDT using live SARS-CoV-2 spiked in different matrices: direct culture supernatant, a dry swab, and a swab in Amies. Additionally, the LOD using dry swab was investigated after 7 days’ storage at − 80 °C of the SARS-CoV-2 serial dilutions. An LOD of ≈ 5.0 × 102 pfu/ml (1.0 × 106 genome copies/ml) in culture media is defined as acceptable by the World Health Organization. Fourteen of 19 Ag-RDTs (ActiveXpress, Espline, Excalibur, Innova, Joysbio, Mologic, NowCheck, Orient, PanBio, RespiStrip, Roche, Standard-F, Standard-Q and Sure-Status) exceeded this performance criteria using direct culture supernatant applied to the Ag-RDT. Six Ag-RDT were not compatible with Amies media and a decreased sensitivity of 2 to 20-fold was observed for eleven tests on the stored dilutions at − 80 °C for 7 days. Here, we provide analytical sensitivity data to guide appropriate test and sample type selection for use and for future Ag-RDT evaluations. |
| format |
article |
| author |
Ana I. Cubas-Atienzar Konstantina Kontogianni Thomas Edwards Dominic Wooding Kate Buist Caitlin R. Thompson Christopher T. Williams Edward I. Patterson Grant L. Hughes Lisa Baldwin Camille Escadafal Jilian A. Sacks Emily R. Adams |
| author_facet |
Ana I. Cubas-Atienzar Konstantina Kontogianni Thomas Edwards Dominic Wooding Kate Buist Caitlin R. Thompson Christopher T. Williams Edward I. Patterson Grant L. Hughes Lisa Baldwin Camille Escadafal Jilian A. Sacks Emily R. Adams |
| author_sort |
Ana I. Cubas-Atienzar |
| title |
Limit of detection in different matrices of 19 commercially available rapid antigen tests for the detection of SARS-CoV-2 |
| title_short |
Limit of detection in different matrices of 19 commercially available rapid antigen tests for the detection of SARS-CoV-2 |
| title_full |
Limit of detection in different matrices of 19 commercially available rapid antigen tests for the detection of SARS-CoV-2 |
| title_fullStr |
Limit of detection in different matrices of 19 commercially available rapid antigen tests for the detection of SARS-CoV-2 |
| title_full_unstemmed |
Limit of detection in different matrices of 19 commercially available rapid antigen tests for the detection of SARS-CoV-2 |
| title_sort |
limit of detection in different matrices of 19 commercially available rapid antigen tests for the detection of sars-cov-2 |
| publisher |
Nature Portfolio |
| publishDate |
2021 |
| url |
https://doaj.org/article/ce468b9e5ac9426487c5b215c756ebef |
| work_keys_str_mv |
AT anaicubasatienzar limitofdetectionindifferentmatricesof19commerciallyavailablerapidantigentestsforthedetectionofsarscov2 AT konstantinakontogianni limitofdetectionindifferentmatricesof19commerciallyavailablerapidantigentestsforthedetectionofsarscov2 AT thomasedwards limitofdetectionindifferentmatricesof19commerciallyavailablerapidantigentestsforthedetectionofsarscov2 AT dominicwooding limitofdetectionindifferentmatricesof19commerciallyavailablerapidantigentestsforthedetectionofsarscov2 AT katebuist limitofdetectionindifferentmatricesof19commerciallyavailablerapidantigentestsforthedetectionofsarscov2 AT caitlinrthompson limitofdetectionindifferentmatricesof19commerciallyavailablerapidantigentestsforthedetectionofsarscov2 AT christophertwilliams limitofdetectionindifferentmatricesof19commerciallyavailablerapidantigentestsforthedetectionofsarscov2 AT edwardipatterson limitofdetectionindifferentmatricesof19commerciallyavailablerapidantigentestsforthedetectionofsarscov2 AT grantlhughes limitofdetectionindifferentmatricesof19commerciallyavailablerapidantigentestsforthedetectionofsarscov2 AT lisabaldwin limitofdetectionindifferentmatricesof19commerciallyavailablerapidantigentestsforthedetectionofsarscov2 AT camilleescadafal limitofdetectionindifferentmatricesof19commerciallyavailablerapidantigentestsforthedetectionofsarscov2 AT jilianasacks limitofdetectionindifferentmatricesof19commerciallyavailablerapidantigentestsforthedetectionofsarscov2 AT emilyradams limitofdetectionindifferentmatricesof19commerciallyavailablerapidantigentestsforthedetectionofsarscov2 |
| _version_ |
1718380936446345216 |